Peta V, Ziol M, Imbert-Bismut F, et al., for the FibroFrance-GHPS-HECAM group

Valentina Peta; Marianne Ziol; Françoise Imbert‐Bismut; Angela Sutton; Denis Monneret; Mona Munteanu; Frederic Charlotte; Olivier Lucidarme; Yen Ngo; An Ngo; Olivier Deckmyn; Tam Pham; Dominique Thabut; Vlad Ratziu; Chantal Housset; Thierry Poynard; Pierre Nahon; FibroFrance‐GHPS‐HECAM group

doi:10.1002/ygh2.339

Peta V, Ziol M, Imbert-Bismut F, et al., for the FibroFrance-GHPS-HECAM group

Valentina Peta, Marianne Ziol, Françoise Imbert‐Bismut, Angela Sutton, Denis Monneret …

Actions du personnel

Télécharger le PDF

Les fichiers sont réservés à un usage autorisé dans les canaux partenaires BioPredictive.

Surveillance Fibrotest Article Our Group

Auteurs (18)

Citation

Valentina Peta, Marianne Ziol, Françoise Imbert‐Bismut, Angela Sutton, Denis Monneret, Mona Munteanu, et al. Peta V, Ziol M, Imbert-Bismut F, et al., for the FibroFrance-GHPS-HECAM group. GastroHep. 2019;1(3):146-153. doi:10.1002/ygh2.339.

Identifiants

DOI: 10.1002/ygh2.339

Tests

Maladies du foie

Atteintes hépatiques

Thèmes

Panier

Votre panier est vide.

Parcourez les publications et utilisez Ajouter au panier sur n'importe quelle page de détail pour constituer une archive ZIP à envoyer aux clients.

Parcourir les publications

Peta V, Ziol M, Imbert-Bismut F, et al., for the FibroFrance-GHPS-HECAM group

Sur le même sujet

An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort.

Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.

Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.

Noninvasive Assessment of Liver Fibrosis.

Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study.

Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).